The Global Leader in Preclinical Ophthalmic Research
EyeCRO provides a fully integrated platform for preclinical ophthalmic drug development, from in-life efficacy studies through bioanalytical analysis, all under one roof. With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies and eyedrop formulations in MiDROPS®.
One Partner. Complete Data.
Most preclinical ophthalmic programs require sponsors to coordinate between separate CROs for in-life studies and bioanalytical work, adding cost, complexity, and delays from sample shipping and cross-site communication. EyeCRO eliminates that friction.
Our dedicated bioanalytical laboratory operates alongside our in-life research teams, providing LC-MS/MS, HPLC, ELISA, and additional capabilities with optimized ocular tissue extraction protocols for mouse, rat, and rabbit. Studies move from dosing to quantification without delays, sample degradation risks, or coordination across vendors.
One study plan. One point of contact. One complete dataset—delivered faster
Microemulsion Drug Ocular Penetration System
MiDROPS®
MiDROPS® was developed to allow for eyedrop formulations of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Our Models
Validated preclinical models across retinal, corneal, inflammatory, and optic nerve disease areas.
Anterior segment / Ocular surface
Allergic Conjunctivitis
Corneal Sensitivity
Corneal Wound Healing
Diabetic Keratopathy
Dry Eye Disease
Inflammation / Autoimmune
Outer retinal degeneration
Blue Light Damage
Geographic Atrophy
Inherited Retinal Degenerations
MNU-induced Retinal Degeneration
Retinal Detachment
Inner retinal degeneration / Optic neuropathy
Retinal vascular / Leakage / Ischemia
Capabilities
From study design to final report, EyeCRO provides end-to-end preclinical research services with best-in-class ophthalmic expertise.
Dosing & Drug Delivery
Intravitreal, subretinal, subconjunctival, topical, and systemic routes of administration across mouse, rat, and rabbit.
Ophthalmic Imaging & Physiology
In vivo retinal imaging including ERG, OCT, fundus photography, and slit-lamp biomicroscopy across multiple species.
Histology & Pathology
Full histological processing, H&E staining, IHC, and digital image quantification for ocular tissue analysis.
Bioanalytical Services
LC-MS/MS, automated sample preparation, multiplex immunoassay, and protein quantification from ocular tissues and fluids.
Proprietary Software & Analysis
Custom-built analysis pipelines for fluorophotometry, retinal imaging quantification, and automated data processing.
News & Events
-
EyeCRO at ARVO 2026
EyeCRO will be attending the 2026 ARVO Annual Meeting in Denver, Colorado, May 3-7. ARVO brings together over 11,000 eye and vision researchers from 75 countries, and it remains the most important meeting in our field for sharing new findings and building collaborations. This year’s theme focuses on how innovative vision research is driving the…
-
EyeCRO Contributes to Evaluation of SPVN06 Gene Therapy
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
-
NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
